Unfortunately, it is clear in the scientific community that these cannabinoids, including CBD, are very poorly absorbed. CBD shows limited oral bioavailability due to its poor aqueous solubility and extensive first-pass metabolism. To overcome these limitations, a novel self-emulsifying drug delivery system (SEDDS) based on VESIsorb® formulation technology was developed. A study was conducted with the objective to evaluate the PK profile of the VESIsorb® CBD formulation in a